Apretude (cabotegravir intramuscular injection) — Medica
Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV)-1 infection
Initial criteria
- Patient weight ≥ 35 kg
- Medication will be administered only if the patient has a negative HIV-1 test result ≤ 1 week prior to the dose of Apretude
- Medication will be administered only if the patient has no signs or symptoms of acute HIV infection, according to the prescriber
- Medication is prescribed as part of a comprehensive HIV-1 prevention strategy (i.e., adherence to administration schedule and safer sex practices, including condoms)
- Medication is prescribed by or in consultation with a physician who specializes in the management of HIV infection
Approval duration
2 months